跳至主要内容
临床试验/NCT00051272
NCT00051272已完成3 期

A Multicenter, Double-blind Randomized Placebo-controlled Comparison of the Effects on Sexual Functioning of Extended-release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20mg) in Outpatients With Moderate to Severe Major Depression Over an Eight-Week Treatment Period

GlaxoSmithKline24 个研究点 分布在 1 个国家目标入组 425 人开始时间: 2003年1月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
425
试验地点
24
主要终点
Percent of subjects with orgasm dysfunction. Change from baseline in HAMD-17 total score.

研究概览

简要总结

This study will evaluate the effects of two antidepression medications on sexual functioning.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Primary diagnosis of Major Depressive Disorder (MDD) with current duration lasting 12 weeks but no greater than 2 years.
  • •Subjects must engage in sexual activity that leads to orgasm at least once every two weeks.
  • •Subject must have normal orgasmic function and be willing to discuss with investigator.

排除标准

  • •Subjects that have arousal or orgasm dysfunction.
  • •Has previously failed to respond to two adequate trials of antidepressants in past 2 years.
  • •Subject has other unstable medical disorders.
  • •Subject has a positive urine test for illicit drug use at screening.

结局指标

主要结局

Percent of subjects with orgasm dysfunction. Change from baseline in HAMD-17 total score.

次要结局

  • Percent of subjects in remission, HAMD-17. Changes in Sexual functioning Questionnaire. CGI-I and CGI-S. Percent of responders, HAMD-17.

研究者

申办方类型
Industry

研究点 (24)

Loading locations...

相似试验